Jesse A. Berlin
Johnson & Johnson Pharmaceutical Research and Development
37 Papers
4.8K Citations
Jesse A. Berlin is an academic researcher from Johnson & Johnson Pharmaceutical Research and Development. The author has contributed to research in topics: Medicine & Odds ratio. The author has an hindex of 21, co-authored 37 publications. Previous affiliations of Jesse A. Berlin include Hospital of the University of Pennsylvania & University of Medicine and Dentistry of New Jersey.
Chat about Author
Papers
Delayed function reduces renal allograft survival independent of acute rejection
Harold I. Feldman,R. Gayner,Jesse A. Berlin,D. A. Roth,Randi Silibovsky,Steven A. Kushner,Kenneth L. Brayman,J.Eileen Burns,Sidney Kobrin,Amy L. Friedman,Robert A. Grossman +10 more
TL;DR: The results suggest that the effect of delayed allograft function is mediated, in part, through mechanisms not involving acute clinical rejection, as well as stable among several subgroups of patients and using alternative definitions of allografted survival and delayed allogsraft function.
•Journal Article
GI complications after orthotopic lung transplantation.
Lubetkin Ei,David A. Lipson,Harold I. Palevsky,Robert M. Kotloff,Jon B. Morris,Gerard T. Berry,Gregory Tino,Ernest F. Rosato,Jesse A. Berlin,Angela Wurster,Larry R. Kaiser,Gary R. Lichtenstein +11 more
TL;DR: GI complications occur in more than one-half of lung transplant recipients early after transplantation and in the absence of identifiable risk factors, suggesting clinicians must be alert to any warning signs and symptoms.
70
Original research article Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: a meta-analysis and formal sensitivity analysis
Sean Hennessy,Jesse A. Berlin,Judith L. Kinman,David J. Margolis,Sue M. Marcus,Brian L. Strom +5 more
- 01 Jan 2001
TL;DR: A meta-analysis and formal sensitivity analysis of studies that examined the relative risk of VTE for desogestrel and gestodene versus levonorgestrel found an association was present when accounting for duration of use and when restricted to the first year of use in new users.
65
Recipient body size and cadaveric renal allograft survival.
Harold I. Feldman,I Fazio,David M. Roth,Jesse A. Berlin,Kenneth L. Brayman,J E Burns,Robert A. Grossman +6 more
TL;DR: All measures of recipient size and metabolic rate were found to be strong and statistically significant predictor of allograft survival adjusted for other predictors of allogsraft survival including allogRAFT rejection, delayed allografted function, recipient race, prior renal transplantation, and donor age.
62